gp100 antigen [clinicaltrials_resource:380e50536f85c83c130be5186501586d]
Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal [clinicaltrials:NCT00003229]Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery [clinicaltrials:NCT00003274]Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma [clinicaltrials:NCT00003339]Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma [clinicaltrials:NCT00003362]Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma [clinicaltrials:NCT00003568]Vaccine Therapy in Treating Patients With Metastatic Melanoma [clinicaltrials:NCT00003792]Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma [clinicaltrials:NCT00003897]Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma [clinicaltrials:NCT00005841]Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma [clinicaltrials:NCT00006113]Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma [clinicaltrials:NCT00006385]Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma [clinicaltrials:NCT00010309]Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma [clinicaltrials:NCT00019175]Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma [clinicaltrials:NCT00019214]Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma [clinicaltrials:NCT00019669]Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma [clinicaltrials:NCT00019721]Vaccine Therapy in Treating Patients With Metastatic Melanoma [clinicaltrials:NCT00019994]Vaccine Therapy in Treating Patients With Melanoma [clinicaltrials:NCT00020358]Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery [clinicaltrials:NCT00025181]Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma [clinicaltrials:NCT00031733]Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma [clinicaltrials:NCT00032045]Vaccine Therapy in Treating Patients With Melanoma of the Eye [clinicaltrials:NCT00036816]Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma [clinicaltrials:NCT00072085]Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma [clinicaltrials:NCT00077532]Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma [clinicaltrials:NCT00091143]Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma [clinicaltrials:NCT00091338]LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery [clinicaltrials:NCT00295958]
intervention [clinicaltrials_vocabulary:intervention]
gp100 antigen [clinicaltrials_resource:380e50536f85c83c130be5186501586d]
Bio2RDF identifier
380e50536f85c83c130be5186501586d
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:380e50536f85c83c130be5186501586d
intervention name [clinicaltrials_vocabulary:intervention-name]
gp100 antigen
identifier
clinicaltrials_resource:380e50536f85c83c130be5186501586d
title
gp100 antigen
@en
type
label
gp100 antigen [clinicaltrials_resource:380e50536f85c83c130be5186501586d]
@en